Clinical data | |
---|---|
Trade names | Eulexin, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697045 |
Pregnancy category |
|
Routes of administration |
By mouth |
ATC code | L02BB01 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | >90% |
Protein binding | 94 to 96% |
Biological half-life | 8 hours (for 2-hydroxyflutamide) |
Excretion | >90% via urine |
Identifiers | |
|
|
Synonyms | Niftolide; SCH-13521; 4'-nitro-3'-trifluoromethylisobutyranilide |
CAS Number | 13311-84-7 |
PubChem (CID) | 3397 |
IUPHAR/BPS | 6943 |
DrugBank | DB00499 |
ChemSpider | 3280 |
UNII | 76W6J0943E |
KEGG | D00586 |
ChEBI | CHEBI:5132 |
ChEMBL | CHEMBL806 |
ECHA InfoCard | 100.033.024 |
Chemical and physical data | |
Formula | C11H11F3N2O3 |
Molar mass | 276.212 g/mol |
3D model (Jmol) | Interactive image |
Melting point | 111.5 to 112.5 °C (232.7 to 234.5 °F) |
|
|
|
|
Flutamide, sold under the brand name Eulexin among others, is a synthetic, non-steroidal antiandrogen (NSAA) used primarily to treat prostate cancer. It acts as a selective antagonist of the androgen receptor (AR), competing with androgens such as testosterone and its powerful active metabolite dihydrotestosterone (DHT) for binding to ARs in the prostate gland. By doing so, it prevents them from stimulating the prostate cancer cells to grow. In addition to its use in prostate cancer, flutamide has been used to treat hyperandrogenism (excess androgen levels) in women, such as in those with polycystic ovary syndrome (PCOS), and hirsutism. Flutamide has been largely replaced by newer NSAAs, namely bicalutamide and enzalutamide, due particularly to better safety, tolerability, and pharmacokinetic profiles.
GnRH is released by the hypothalamus in a pulsatile fashion; this causes the anterior pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH stimulates the testes to produce testosterone, which is metabolized to DHT by the enzyme 5α-reductase.